Leukotrienes as common intermediates in the cyclic AMP dependent and independent pathways in adrenal steroidogenesis.
Aldosterone secretion from adrenal glomerulosa cells can be stimulated by angiotensin II (AII), extracellular potassium and adrenocorticotropin (ACTH). Since the mitochondria can recognize factors generated by AII (cyclic-AMP-independent) and ACTH (cyclic AMP dependent), it is reasonable to postulate the existence of a common intermediate in spite of a different signal transduction mechanism. We have evaluated this hypothesis by stimulation of mitochondria from glomerulosa gland with fractions isolated from glomerulosa gland stimulated with AII or from fasciculata gland stimulated with ACTH; the same fractions were tested using mitochondria from fasciculata cells. Postmitochondrial fractions (PMTS) obtained after incubation of adrenal zona glomerulosa with or without AII (10(-7) M) or ACTH (10(-10) M), were able to increase net progesterone synthesis 5-fold in mitochondria isolated from non-stimulated rat zona glomerulosa. In addition, AII in zona glomerulosa produced in vitro steroidogenic fractions that were able to stimulate mitochondria from zona fasciculata cells. Inhibitors of arachidonic acid release and metabolism blocked corticosterone production in fasciculata cells stimulated with ACTH. This concept is supported by the experiment in which bromophenacylbromide and nordihydroguaiaretic acid also blocked the formation of an activated PMTS. In fact, non-activated PMTS, in the presence of exogenous arachidonic acid AA, behaved as an activated PMTS from ACTH stimulated cells. We suggest that the mechanisms of action of ACTH and AII involve an increase in the release of AA and an activation of the enzyme system which converts AA in leukotriene products.
Solano
A R
AR
Centro de Investigaciones Endocrinológicas, Hospital de Niños R. Gutiérrez, Buenos Aires, Argentina.
Dada
L A
LA
Luz Sardañons
M
M
Sánchez
M L
ML
Podestá
E J
EJ
D000098:Acetophenones / Q000494:pharmacology; D000311:Adrenal Glands / Q000187:drug effects / Q000378:metabolism*; D000324:Adrenocorticotropic Hormone / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D016718:Arachidonic Acid; D001095:Arachidonic Acids / Q000037:antagonists & inhibitors / Q000378:metabolism; D003345:Corticosterone / Q000096:biosynthesis; D000242:Cyclic AMP / Q000494:pharmacology*; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D008297:Male; D009637:Masoprocol / Q000494:pharmacology; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D011374:Progesterone / Q000096:biosynthesis; D051381:Rats; D013256:Steroids / Q000096:biosynthesis*
D000098:Acetophenones; D001095:Arachidonic Acids; D005231:Fatty Acids, Unsaturated; D013256:Steroids; D000804:Angiotensin II; D016718:Arachidonic Acid; D011374:Progesterone; D009637:Masoprocol; D000324:Adrenocorticotropic Hormone; D000242:Cyclic AMP; C006821:4-bromophenacyl bromide; D003345:Corticosterone